
GW Pharmaceuticals Plc - Strategic SWOT Analysis Review
Description
GW Pharmaceuticals Plc - Strategic SWOT Analysis Review
- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
GW Pharmaceuticals Plc (GW Pharmaceuticals), a subsidiary of Jazz Pharmaceuticals, is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also advancing its pipeline for the treatment of Rett syndrome, spasticity associated with spinal cord injury, post-traumatic stress disorder, schizophrenia, epilepsy, and neonatal hypoxic-ischemic encephalopathy. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, the UK.
GW Pharmaceuticals Plc Key Recent Developments
Apr 28,2021: GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
Feb 23,2021: Jazz Pharmaceuticals to Acquire GW Pharmaceuticals
Feb 16,2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
Jan 11,2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Reasons to Buy
- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
GW Pharmaceuticals Plc (GW Pharmaceuticals), a subsidiary of Jazz Pharmaceuticals, is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also advancing its pipeline for the treatment of Rett syndrome, spasticity associated with spinal cord injury, post-traumatic stress disorder, schizophrenia, epilepsy, and neonatal hypoxic-ischemic encephalopathy. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, the UK.
GW Pharmaceuticals Plc Key Recent Developments
Apr 28,2021: GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
Feb 23,2021: Jazz Pharmaceuticals to Acquire GW Pharmaceuticals
Feb 16,2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
Jan 11,2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
29 Pages
- Section 1 - About the Company
- GW Pharmaceuticals Plc - Key Facts
- GW Pharmaceuticals Plc - Key Employees
- GW Pharmaceuticals Plc - Key Employee Biographies
- GW Pharmaceuticals Plc - Major Products and Services
- GW Pharmaceuticals Plc - History
- GW Pharmaceuticals Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- GW Pharmaceuticals Plc - Business Description
- GW Pharmaceuticals Plc - SWOT Analysis
- SWOT Analysis - Overview
- GW Pharmaceuticals Plc - Strengths
- GW Pharmaceuticals Plc - Weaknesses
- GW Pharmaceuticals Plc - Opportunities
- GW Pharmaceuticals Plc - Threats
- GW Pharmaceuticals Plc - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- GW Pharmaceuticals Plc, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- Apr 28, 2021: GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
- Feb 16, 2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
- Jan 11, 2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- GW Pharmaceuticals Plc, Key Facts
- GW Pharmaceuticals Plc, Key Employees
- GW Pharmaceuticals Plc, Key Employee Biographies
- GW Pharmaceuticals Plc, Major Products and Services
- GW Pharmaceuticals Plc, History
- GW Pharmaceuticals Plc, Other Locations
- GW Pharmaceuticals Plc, Subsidiaries
- GW Pharmaceuticals Plc, Key Competitors
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- GW Pharmaceuticals Plc, Recent Deals Summary
- List of Figures
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.